Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment

Hinrich Wieder(Klinikum rechts der Isar), Wolfgang Weber(Nuklearmedizinische Klinik des Klinikums rechts der Isar), Frank Zimmermann(TUM Klinikum), Florian Lordick(Leipzig University), Ambros J. Beer(TUM Klinikum), H. J. Stein(LMU Klinikum), U. Fink(Technical University of Munich), Karen Becker(Technical University of Munich), Markus Schwaiger(Technical University of Munich), J. R. Siewert(Technical University of Munich), Björn L.D.M. Brücher(TUM Klinikum)
Journal of Clinical Oncology
February 27, 2004
10.1200/jco.2004.07.122
Cited by 460

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k